Krystal Biotech, Inc. (KRYS) Tops Q4 EPS by 31c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $1.52, $0.31 better than the analyst estimate of $1.21. Revenue for the quarter came in at $91.14 million versus the consensus estimate of $91.63 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results